Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price0.06 USD
Fair value0.14
RatingAVOID
Our investment reviews on this name
2026-10-18Read Distribution0.07-13.8% to today ✓Markdown gives way to Distribution after a 19% slide in 7 days
2026-10-11Read Markdown0.09-29.8% to today ✓Distribution gives way to Markdown after a 6% slide in 7 weeks
2026-08-23Read Distribution0.10-33.9% to today ✓Markup gives way to Distribution after a 21% slide in 7 weeks
2026-07-02Read Markup0.12-47.5% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
BioLargo, Inc. holds its Distribution at $0.06. The statistical read favours the sellers, held for 6 days.
As held on the ledger · 2026-10-28
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 6 days
Price at the screen
$0.06
Valuation
N/A trailing · -2.30 forward price to earnings
Values screen
PASS
Beta
-0.12
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.00%
Below 33%
Interest-bearing debt is just 0.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
2.58%
Below 5%
Only 2.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
BioLargo, clears all five screens. Its business is in a permissible area, its debt is near-nil, and interest is about 3% of its income, under the ~5% line, so it passes.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BLGO's ethical verdict changes
Today BLGO passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads AVOID: it trades at roughly a 56% discount to our $0.14 fair value.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. A 55.6% margin of safety to the base estimate.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At -2.3x forward earnings, the price already runs ahead of the business. Our fair value sits at $0.14, below where it trades today.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BLGO trades on OQX. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 18.6% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (1 analysts) rates it strong buy, with a mean price target of $0.
2026-10-11Markdown · changed$0.09+0.0%Entry 7
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (1 analysts) rates it strong buy, with a mean price target of $0.
2026-10-02Distribution$0.09-5.8%Entry 6
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.8% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (1 analysts) rates it strong buy, with a mean price target of $0.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 13.4% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (1 analysts) rates it strong buy, with a mean price target of $0.
2026-07-23Markup$0.11-8.3%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 8.3% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (1 analysts) rates it strong buy, with a mean price target of $0.
2026-07-18Markup$0.12+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (1 analysts) rates it strong buy, with a mean price target of $0.
2026-07-03Markup$0.12+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$0.12Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.